BIOMIMESYS® 3D technology is a natural HA-based scaffold to better mimic the tissue microenvironment and provide more predictive tools for drug development. The BIOMIMESYS® products are formed by crosslinking reaction of hydrosoluble modified hyaluronic acid and others matrix components with ADH (adipic acid dihydrazide), to mimic the extracellular matrix (ECM). Depending on the organ, ECM components vary and are present in different proportions, allowing a more or less dense and compact cellular environment. BIOMIMESYS® 3D technology allows us to reproduce the cell microenvironment of each organ.
Click here to get more information!
To ensure personalised treatment for familial hypercholesterolemia
To develop relevant 3D models of different tumors, in order to better assess the efficiency of anticancer therapies.
A holistic approach to address brain delivery
Face to the high failure of drug candidate in clinical trial, in particular involving the brain, we goal to develop more relevant and more predictive in vitro models for preclinical assessment, in the aim to early select molecules of interest, in term of efficacy and safety.
To design and industrialize new pharmacological in vitro assays for the screening of compounds/biopharmaceuticals in 3D
To develop the technological platform to produce lab-grown meats. The project is funded by EUREKA and the national funding agencies associated with the Eurostars program.
To develop a universal “plug-and-play” liver-on-chip platform mimicking the major events occurring in the liver sinusoid in order to predict the hepatoxicity of drugs.
To explore the use of AI technologies to improve different steps of 3D biological picture exploitation
Metastasis is the leading cause of death in many cancers. Metastases are particularly harmful when they affect vital organs such as the brain or liver, severely compromising the patient’s quality of life and leading to Read more…
In recent years, 3D cell culture has emerged as a promising approach to studying the immune system and its interactions with cancer cells. Indeed, 3D cell culture mimics better the natural architecture of tissues and Read more…
Currently in Japan, it’s already been a week in Asia. Time goes by very quickly with 3 days of events, many appointments, visits from potential partners, a visit to the Kobe biopark and JETRO, and Read more…
This week we pleased to take part to the Imaging User Meeting 2023 of Molecular Devices. The event took place on 9 and 10 May in Copenhagen. It was an amazing opportunity to share our Read more…
Nathalie, founder, CEO and CSO of HCS Pharma will be present in BIO international convention that takes place in Boston, USA from the 5th to the 8th of June. Is it the place to be Read more…
The Building Biology in 3D symposium of the Society for Laboratory Automation and Screening (SLAS) took place in Cambridge, United Kingdom, on March 20th and 21th 2023. This congress was the opportunity to discover the Read more…
A driver oncogene is a gene that, when activated by mutation or altered in expression, contributes importantly to the development and progression of cancer. In other words, alteration of this kind of genes lead to Read more…
… And it is right ! “Biomimesys technology can bring several advantages in immuno-oncology by providing a more physiologically relevant 3D cell culture model for research. This technology uses a bioinspired extracellular matrix to create Read more…
Poster presented during the SLAS Building Biology in 3D symposium event in Cambridge on April, 21th 2023. Title: 3D cell culture taking into account the extracellular matrix for phenotypic screening in the frame of Parkinson’s Read more…
The event “Research and Innovation 2023 – Accelerating future DD” of The European Laboratory Research and Innovation Group (ELRIG) took place in Cambridge on March 29th and 30th 2023. Our project leader Dr. Veronique De Read more…
HCS Pharma is very pleased to participate to “Building Biology in 3D” symposium of the Society for Laboratory Automation and Screening (SLAS), in Cambridge, United Kingdom 20-21 April 2023. Veronique De Conto, our project leader Read more…
Follow the webinar « From 2D to 3D » with miss Oceane Guyot, R&D dermarto cosmetology Project leader on ; – Tuesday, April 25, 2023 – 9AM (CEST) / 3PM (CST) / 4PM (JST) / 3AM (EST) – Read more…
It is with great pleasure that we announce the reinforcement of our collaboration about lung cancer between HCS Pharma and TARGET team of the OncoLille Institute (Team “Efficacy and resistance to anti-tumor targeted therapies”, CANTHER Read more…
Zebrafish is a popular model organism for biomedical research worldwide beacause is an ideal model for studying embryonic development and genetic disorders. They have an impressive ability to regenerate damaged tissues, including fins, heart, and Read more…
We will be pleased to meet you in Paris from the 28th to 30th of March. Join Thierry DE CATHEU Business Director, Mathieu LAOUENAN Chief Commercial Officer, Paul COUVREUR and Rita HIEN Junior Business Developpers. Read more…
Organoids are three-dimensional structures made of cells, which can be derived from stem cells to mimic the structure and function of real organs. They are useful tools for studying human development, disease modeling, drug screening, Read more…
Welcome to HCS Pharma series of webinars and please register for free to the ones you want to attend. You will receive the specific Zoom link within a week prior the event.You will learn more Read more…
HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS
See on map
+33 769 999 137
Only for customers please, if you have another interest use the form contact.
